Results 141 to 150 of about 31,989 (296)

A cost–benefit analysis of the implementation and scale‐up of harm reduction interventions in the Australian Capital Territory

Addiction, EarlyView.
Abstract Background and aims Harm reduction interventions aim to reduce negative consequences of drug use. We aimed to estimate the cost, health impact and economic benefits of current, expanded and new harm reduction interventions for people who use drugs in the Australian Capital Territory.
Anna L. Bowring, Tom Tidhar, Anna Olsen, Christopher Bailie, Kelvin Burke, Rowan Martin‐Hughes, Helen Keane, Paul Dietze, Nick Scott   +8 more
wiley   +1 more source

Cannabis-Based Medicines ??? GW Pharmaceuticals

Drugs in R & D, 2003
GW Pharmaceuticals is undertaking a major research programme in the UK to develop and market distinct cannabis-based prescription medicines [THC:CBD, High THC, High CBD] in a range of medical conditions. The cannabis for this programme is grown in a secret location in the UK. It is expected that the product will be marketed in the US in late 2003. GW's
openaire   +2 more sources

One Toke Over the Line: The Proliferation of State Medical Marijuana Laws [PDF]

, 2010
[Excerpt] “Marijuana has been used for medicinal purposes for at least five thousand years. In fact, it was used medicinally in the United States up until the twentieth century when antidrug zealots managed to prohibit it.
Grandel, Troy E.
core   +1 more source

Detecting cannabis use reduction through biochemical verification of urinary cannabinoids: An aggregated analysis of cannabis use disorder treatment trials examining average reductions and individual cut‐points

Addiction, EarlyView.
Abstract Background and aims Currently, there is no data‐driven cannabis reduction metric using biochemical verification, which represents a significant gap in cannabis harm reduction research, treatment and policy. Using aggregated data from 7 cannabis use disorder treatment trials, the aims of this analysis were to 1) determine if decreases in self ...
Erin A. McClure, Brian Neelon, Rachel L. Tomko, Ashley Dowd, Kevin M. Gray, Aimee L. McRae‐Clark, Nathaniel Baker   +6 more
wiley   +1 more source

Varenicline for cannabis use disorder: A randomized controlled trial

Addiction, EarlyView.
Abstract Background and aims Although cannabis use is widespread and prevalence of cannabis use disorder (CUD) is increasing, limited advancements have been made in CUD medication development. The objective of this study was to test the efficacy of varenicline with medical management for reducing cannabis use in treatment‐seeking individuals with CUD ...
Aimee L. McRae‐Clark, Kevin M. Gray, Nathaniel L. Baker, Brian J. Sherman, Bryan Tolliver, Jessica Burt, Alonzo Steplight, Elizabeth Chapman, Amanda Wagner   +8 more
wiley   +1 more source

A meta‐analysis of sexual orientation inequities in substance use among youth

Addiction, EarlyView.
Abstract Background and Aims Sexual minority youth report significantly higher rates of substance use than heterosexual youth, yet a comprehensive and systematic evaluation and synthesis of the magnitude of this inequity has not been conducted. The purpose of this study was to conduct a meta‐analysis to assess the magnitude of overall inequities in ...
Ethan H. Mereish, Hyemin Lee, Jeremy T. Goldbach, Sophie Hathaway, Emily A. Hennessy   +4 more
wiley   +1 more source

Commentary on Borodovsky et al.: Enhancing research on THC quantification—Consumer awareness through accurate labelling

Addiction, Volume 120, Issue 4, Page 686-687, April 2025.
Rachel Lees Thorne, Tom P. Freeman
wiley   +1 more source

Addiction‐related problems in Japan: A regional perspective

Addiction, EarlyView.
Abstract Japan's addiction landscape appears paradoxical. The lifetime use of illicit drugs is among the lowest in Organisation for Economic Cooperation and Development countries, but harm from alcohol, tobacco, and gambling ranks among the world's highest.
Soichiro Ide, Yoko Nishitani, Masahiko Sumitani, Masabumi Minami, Tadashi Isa, Masako Iseki, Michiko Ohkura, Hitoshi Okamoto, Tetsuro Kikuchi, Yuko Sekino, Hidehiko Takahashi, Kenji Takeuchi, Atsumi Nitta, Takeshi Honjo, Hiroshi Matsumoto, Tsuyoshi Miyakawa, Toshiya Murai, Toshihiko Matsumoto, Kazuyuki Nakagome, Kazutaka Ikeda   +19 more
wiley   +1 more source

Terapias alternativas con cannabis en ansiedad y sintomatología relativa al sistema nervioso central [PDF]

, 2017
En esta revisión bibliográfica se ha intentado dar una visión general sobre el uso de cannabis y las terapias alternativas con esta sustancia en dos áreas relevantes para la psicobiología como son la ansiedad (y trastornos donde este síntoma es central ...
Benítez Gómez, María Isabel
core  

Trends in fentanyl‐containing drug samples seized by law enforcement agencies across Canada

Addiction, EarlyView.
Abstract Background and aims Canada's drug toxicity crisis has been largely attributed to a volatile fentanyl‐dominated unregulated drug supply with increasing reports of fentanyl detected in combination with benzodiazepines, stimulants and xylazine.
Shaleesa Ledlie, Ria Garg, Pamela Leece, Gillian Kolla, Elaine Hyshka, Mina Tadrous, Tara Gomes   +6 more
wiley   +1 more source